Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.

@article{Liao2012SafetyAI,
  title={Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.},
  author={Guoyang Liao and Rong Cheng Li and Changgui Li and Mingbo Sun and Yanping Li and Jiayou Chu and Shude Jiang and Qihan Li},
  journal={The Journal of infectious diseases},
  year={2012},
  volume={205 2},
  pages={237-43}
}
BACKGROUND The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. METHODS The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received… CONTINUE READING